No Automatic Review Under O2 Micro
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
KAUFMAN v. MICROSOFT CORPORATION
Before Dyk, Reyna, and Taranto. Appeal from the District Court for the Southern District of New York
Summary: An “automatic” method does not require all steps in the method to be performed without user input and five years delay in bringing a suit is not an undue delay.
Michael Kaufman (“Kaufman”) brought suit against Microsoft for infringement of U.S. Patent No. 7,885,981 (the ’981 patent), which claims methods for automatically generating end-user interfaces. At the pre-trial hearing, Microsoft argued for the first time that the word “automatic” in the preamble of the claims required all steps to be performed without human input, but did not specifically request a claim construction. The jury then found in Kaufman’s favor and awarded $7 million in damages. The District Court denied Microsoft’s post-trial motion for a new trial under O2 Micro because the District Court failed to clarify the meaning of “automatic.” Likewise, the District Court denied Kaufman’s post-trial motion for prejudgment interest, finding that Kaufman had unduly delayed brining suit. Both parties appealed.
On appeal, the Federal Circuit rejected Microsoft’s request for a new trial. The Federal Circuit explained that, though O2 Micro requires the court resolve claim construction issues, Microsoft forfeited the right to raise an O2 Micro issue when it failed to propose a construction of “automatic.” Further, the Federal Circuit rejected Microsoft’s argument that the preamble reciting an “automatic” method requires all the steps in the method to be automatic. Finally, the Federal Circuit found the District Court had abused its discretion by not awarding Kaufman prejudgment interest. The Federal Circuit explained that, though Kaufman brought suit five years after infringement was discovered, this did not justify a finding of undue delay without other evidence of “self-serving” litigation tactics.
Editor: Paul Stewart
Written by: Matthew Friedrichs & Daniel P. Hughes
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…